Quick Answer
Cocrystal Pharma, Inc. reported Research And Development Expense of $5.06 million for the year ending 2025.
- Cocrystal Pharma, Inc. showed a decrease of -59.7% in Research And Development Expense from 2024 to 2025.
- This data is from Cocrystal Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $221.6 thousand | Q2 2012: $206.5 thousand | Q3 2012: $155.9 thousand | Q1 2013: $1.01 million | Q2 2013: $980.0 thousand | Q3 2013: $950.0 thousand | Q1 2014: $967.0 thousand | Q2 2014: $888.0 thousand | Q3 2014: $866.0 thousand | Q1 2015: $1.56 million | Q2 2015: $1.95 million | Q3 2015: $2.18 million | Q4 2015: $38.70 million | Q1 2016: $3.34 million | Q2 2016: $2.37 million | Q3 2016: $2.09 million | Q4 2016: $93.88 million | Q1 2017: $2.07 million | Q2 2017: $1.39 million | Q3 2017: $1.39 million | Q4 2017: $1.10 million | Q1 2018: $877.0 thousand | Q2 2018: $1.12 million | Q3 2018: $1.47 million | Q1 2019: $878.0 thousand | Q2 2019: $1.09 million | Q3 2019: $1.08 million | Q1 2020: $1.28 million | Q2 2020: $1.98 million | Q3 2020: $2.08 million | Q1 2021: $1.58 million | Q2 2021: $2.56 million | Q3 2021: $2.11 million | Q1 2022: $2.87 million | Q2 2022: $2.36 million | Q3 2022: $3.87 million | Q1 2023: $3.91 million | Q2 2023: $2.80 million | Q3 2023: $4.19 million | Q1 2024: $2.95 million | Q2 2024: $4.31 million | Q3 2024: $3.24 million | Q1 2025: $1.36 million | Q2 2025: $1.12 million | Q3 2025: $954.0 thousand.
- Over the full 16 years of available data (2010 to 2025), Cocrystal Pharma, Inc.'s Research And Development Expense has grown by 1,998.6%.
- Historical annual values: Fiscal year 2025: $5.06 million | Fiscal year 2024: $12.54 million | Fiscal year 2023: $15.17 million | Fiscal year 2022: $12.39 million | Fiscal year 2021: $8.79 million | Fiscal year 2020: $6.03 million | Fiscal year 2019: $4.00 million | Fiscal year 2018: $4.67 million | Fiscal year 2017: $5.82 million | Fiscal year 2016: $101.68 million | Fiscal year 2015: $47.26 million | Fiscal year 2014: $4.07 million | Fiscal year 2013: $3.86 million | Fiscal year 2012: $489.3 thousand | Fiscal year 2011: $423.2 thousand | Fiscal year 2010: $240.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: